FI3711758T3 - Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi - Google Patents
Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi Download PDFInfo
- Publication number
- FI3711758T3 FI3711758T3 FIEP18878222.1T FI18878222T FI3711758T3 FI 3711758 T3 FI3711758 T3 FI 3711758T3 FI 18878222 T FI18878222 T FI 18878222T FI 3711758 T3 FI3711758 T3 FI 3711758T3
- Authority
- FI
- Finland
- Prior art keywords
- absence
- epilepsy
- use according
- compound
- seizure
- Prior art date
Links
- 206010010904 Convulsion Diseases 0.000 title claims 26
- 208000028311 absence seizure Diseases 0.000 title claims 24
- 206010034759 Petit mal epilepsy Diseases 0.000 title claims 18
- -1 carbamate compound Chemical class 0.000 title claims 7
- 208000003554 absence epilepsy Diseases 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 8
- 206010015037 epilepsy Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 208000016132 Epilepsy with myoclonic absences Diseases 0.000 claims 2
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 2
- 208000022120 Jeavons syndrome Diseases 0.000 claims 2
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000002033 Myoclonus Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 2
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170151248 | 2017-11-14 | ||
| PCT/KR2018/013761 WO2019098628A1 (ko) | 2017-11-14 | 2018-11-13 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3711758T3 true FI3711758T3 (fi) | 2024-05-13 |
Family
ID=66540315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18878222.1T FI3711758T3 (fi) | 2017-11-14 | 2018-11-13 | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200352907A1 (enExample) |
| EP (1) | EP3711758B1 (enExample) |
| JP (2) | JP7258901B2 (enExample) |
| KR (1) | KR102739584B1 (enExample) |
| CN (1) | CN111432812A (enExample) |
| AU (1) | AU2018367729B2 (enExample) |
| BR (1) | BR112020009265A2 (enExample) |
| CA (1) | CA3081223A1 (enExample) |
| DK (1) | DK3711758T3 (enExample) |
| ES (1) | ES2982316T3 (enExample) |
| FI (1) | FI3711758T3 (enExample) |
| IL (1) | IL274428B2 (enExample) |
| MX (1) | MX2020004972A (enExample) |
| PL (1) | PL3711758T3 (enExample) |
| PT (1) | PT3711758T (enExample) |
| WO (1) | WO2019098628A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113052A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus |
| CN116143717B (zh) * | 2021-11-22 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 一种氘代氨基甲酸酯化合物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6383764B1 (en) | 2000-04-28 | 2002-05-07 | The Regents Of The University Of California | Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP) |
| KR100534556B1 (ko) | 2001-10-26 | 2005-12-08 | 주식회사 오리엔트바이오 | 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
| EP1707204A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US8501436B2 (en) * | 2009-06-22 | 2013-08-06 | Sk Biopharmaceuticals Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| KR102489052B1 (ko) | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| DK3556349T3 (da) | 2016-12-14 | 2022-01-03 | Sk Biopharmaceuticals Co Ltd | Parenteralt flydende præparat omfattende en carbamatforbindelse |
| CA3073925A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Treatment of cns conditions |
-
2018
- 2018-11-13 JP JP2020544727A patent/JP7258901B2/ja active Active
- 2018-11-13 MX MX2020004972A patent/MX2020004972A/es unknown
- 2018-11-13 AU AU2018367729A patent/AU2018367729B2/en active Active
- 2018-11-13 ES ES18878222T patent/ES2982316T3/es active Active
- 2018-11-13 KR KR1020207013843A patent/KR102739584B1/ko active Active
- 2018-11-13 DK DK18878222.1T patent/DK3711758T3/da active
- 2018-11-13 US US16/763,636 patent/US20200352907A1/en active Pending
- 2018-11-13 EP EP18878222.1A patent/EP3711758B1/en active Active
- 2018-11-13 WO PCT/KR2018/013761 patent/WO2019098628A1/ko not_active Ceased
- 2018-11-13 PT PT188782221T patent/PT3711758T/pt unknown
- 2018-11-13 CN CN201880073833.7A patent/CN111432812A/zh active Pending
- 2018-11-13 CA CA3081223A patent/CA3081223A1/en active Pending
- 2018-11-13 PL PL18878222.1T patent/PL3711758T3/pl unknown
- 2018-11-13 BR BR112020009265-7A patent/BR112020009265A2/pt unknown
- 2018-11-13 FI FIEP18878222.1T patent/FI3711758T3/fi active
-
2020
- 2020-05-04 IL IL274428A patent/IL274428B2/en unknown
-
2023
- 2023-04-05 JP JP2023061633A patent/JP7578747B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3711758B1 (en) | 2024-03-27 |
| PL3711758T3 (pl) | 2024-07-01 |
| ES2982316T3 (es) | 2024-10-15 |
| MX2020004972A (es) | 2020-08-24 |
| IL274428A (en) | 2020-06-30 |
| IL274428B2 (en) | 2023-08-01 |
| US20200352907A1 (en) | 2020-11-12 |
| AU2018367729B2 (en) | 2024-06-13 |
| KR102739584B1 (ko) | 2024-12-06 |
| RU2020119292A3 (enExample) | 2022-02-24 |
| WO2019098628A1 (ko) | 2019-05-23 |
| DK3711758T3 (da) | 2024-04-08 |
| JP2021503010A (ja) | 2021-02-04 |
| KR20200074153A (ko) | 2020-06-24 |
| JP7578747B2 (ja) | 2024-11-06 |
| AU2018367729A1 (en) | 2020-05-21 |
| EP3711758A1 (en) | 2020-09-23 |
| JP2023085469A (ja) | 2023-06-20 |
| CA3081223A1 (en) | 2019-05-23 |
| BR112020009265A2 (pt) | 2020-10-20 |
| RU2020119292A (ru) | 2021-12-15 |
| PT3711758T (pt) | 2024-04-22 |
| EP3711758A4 (en) | 2021-08-04 |
| CN111432812A (zh) | 2020-07-17 |
| IL274428B1 (en) | 2023-04-01 |
| JP7258901B2 (ja) | 2023-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| FI3711758T3 (fi) | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| EA201591353A1 (ru) | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента | |
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| WO2010017545A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2011159124A3 (ko) | Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
| RU2014124029A (ru) | Фенилкарбаматные соединения для применения в облегчении или лечении боли и невропатической боли | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| WO2012177893A3 (en) | Trpm8 antagonists and their use in treatments | |
| WO2014128669A3 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| EA200401614A1 (ru) | O-замещённые гидроксиарильные производные | |
| CA2791702A1 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| RU2015143841A (ru) | Ингибиторы hdac | |
| WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | |
| WO2011149288A2 (ko) | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| CA2881554C (en) | Methods for inhibiting fascin | |
| MX2013007937A (es) | Nuevo derivado de indol o indazol o sal del mismo. | |
| PT1753723E (pt) | Derivados de quinolina substituída como inibidores de quinesina mitótica | |
| CA2602573A1 (en) | Protective agent for retinal neuronal cell containing prostaglandin f2 .alpha. derivative as active ingredient | |
| WO2010076033A9 (en) | Toluidine sulfonamides and their use | |
| WO2012112447A3 (en) | Histone deacetylase inhibitors and methods of use thereof | |
| CA2609213A1 (en) | Use of cinnamates to inhibit proteasome activity |